Miv Therapeutics, Inc. (IVT) Tops Q2 EPS by 1c

Miv Therapeutics, Inc. (NYSE: IVT) reported Q2 EPS of $0.03, $0.01 better than the analyst estimate of $0.02. Revenue for the quarter came in at $64.69 million versus the consensus estimate of $62.7 million.

For earnings history and earnings-related data on Miv Therapeutics, Inc. (IVT) click here.

You May Also Be Interested In

• Jefferies sees a buying opportunity in this S&P 500 sector
• Live Ventures (LIVE) Reports Q3 Loss of $0.34
• Wolfe Research upgrades Biogen, AbbVie on pipeline strength and valuation